The marketing authorisation for Viracept has not been renewed by the marketing-authorisation holder and is now withdrawn.
Viracept : EPAR - Summary for the public (PDF/527.82 KB)
First published: 27/08/2008
Last updated: 10/06/2014
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Roche Registration Ltd.
|Date of issue of marketing authorisation valid throughout the European Union||
23/01/2013 Viracept - EMEA/H/C/000164 - N/0121
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Antivirals for systemic use
Viracept is indicated in antiretroviral combination treatment of human-immunodeficiency-virus (HIV-1)-infected adults, adolescents and children of three years of age and older.
In protease-inhibitor (PI)-experienced patients, the choice of nelfinavir should be based on individual viral resistance testing and treatment history.
European Medicines Agency finalises review of medicines concerned by Roche pharmacovigilance inspection19/11/2013
European Medicines Agency starts infringement procedure to investigate Roche's alleged non-compliance with pharmacovigilance obligations23/10/2012
Studies assessed by the European Medicines Agency indicate no increased risk of developing cancer for patients who have taken Viracept contaminated with ethyl mesilate24/07/2008
European Medicines Agency agrees on action plan following the recall of Viracept and recommends suspension of the marketing authorisation21/09/2007